<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413231</url>
  </required_header>
  <id_info>
    <org_study_id>Investigational Plan #078</org_study_id>
    <nct_id>NCT00413231</nct_id>
  </id_info>
  <brief_title>Valor II: The Valiant Thoracic Stent Graft System Clinical Study</brief_title>
  <official_title>The Valiant Thoracic Stent Graft System. The Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft System in the Treatment of Descending Thoracic Aneurysms of Degenerative Etiology in Subjects Who Are Candidates for Endovascular Repair.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to study safety and effectiveness of the Valiant Thoracic Stent Graft
      to treat thoracic aortic aneurysms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aorta is a large blood vessel that carries blood away from the heart to the organs in the
      rest of the body. An aneurysm is a weakening in the artery wall that will become a bulge in
      the aorta. If left untreated, this bulge may continue to grow larger and may rupture (break
      open) with fatal consequences. In this research study we are investigating a device that can
      be placed in the aorta to exclude the weakened part of the artery wall and restore blood
      flow. Information will be collected on the performance of the device for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants That Did NOT Experience Aneurysm-Related Mortality (Post-market Primary Endpoint)</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Evaluation of the ARM-free rate in subjects implanted with the Valiant Thoracic Stent Graft five years post-implantation by comparing it to a pre-defined performance goal (PG) based on an analysis of ARM-free rates from TEVAR data and on results from the VALOR (Talent Thoracic Endoluminal Stent Graft, IDE G980116) clinical study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Successful Aneurysm Treatment (Primary Effectiveness Endpoint)</measure>
    <time_frame>At 12-month post procedure</time_frame>
    <description>Percentage of subjects with absence of both: a) aneurysm growth of more than 5 mm at the 12-month visit relative to the 1-month visit; and b) secondary procedure due to type I or III endoleak performed or recommended at or before the 12-month visit. Success means a subject experienced neither a nor b.
Type I: endoleak in continuity with the proximal anchoring site(proximal endoleak) or the distal anchoring site(distal endoleak)of the device.
Type III: endoleak is present in the mid-graft region due to defect of fabric or between the segments of the modular graft (junctional endoleak).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Died (Primary Safety Endpoint: All-Cause Mortality) &gt; &gt;</measure>
    <time_frame>Within 12-months post treatment</time_frame>
    <description>The percentage of participants who died within 12-months of the initial procedure, whether or not the cause of death was related to the study device, procedure, or condition treated.
&gt;
&gt; Note: All-cause mortality endpoint is not directly related to successful aneurysm treatment, which pertains to the absence of aneurysm growth and secondary procedure due to Type I and III endoleaks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects That Experienced Successful Deployment and Delivery of the Stent Graft at Implant</measure>
    <time_frame>At implant</time_frame>
    <description>Percentage of subjects that experienced successful deployment and delivery of the stent graft at implant. Successful deployment and delivery of the stent graft is used to measure effectiveness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Perioperative Mortality</measure>
    <time_frame>Within 30 days post treatment</time_frame>
    <description>Percentage of subjects that experienced perioperative mortality. Perioperative morality is defined as all-cause mortality within 30 days after index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Paraplegia</measure>
    <time_frame>Within 30 days post treatment</time_frame>
    <description>Percentage of subjects that experienced paraplegia within 30 days post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Paraparesis</measure>
    <time_frame>Within 30 days post treatment</time_frame>
    <description>Percentage of subjects that experienced paraparesis within 30 days post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Secondary Procedures Due to Endoleak After Discharge</measure>
    <time_frame>Within 30 days post treatment</time_frame>
    <description>Percentage of subjects that experienced secondary procedures due to endoleak after discharge within 30 days post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced One or More Major Adverse Events</measure>
    <time_frame>Within 30 days post treatment</time_frame>
    <description>Percentage of subjects that experienced one or more major adverse events within 30 days post treatment, regardless of relatedness to study device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Aneurysm-related Mortality</measure>
    <time_frame>Within 12 months post treatment</time_frame>
    <description>Percentage of subjects that experienced aneurysm-related mortality within 12 months post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experience Aneurysm Rupture</measure>
    <time_frame>Within 12 months post treatment</time_frame>
    <description>Percentage of subjects that experience aneurysm rupture within 12 months post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Conversion to Open Surgical Repair</measure>
    <time_frame>Within 12 months post treatment</time_frame>
    <description>Percentage of subjects that experienced conversion to open surgical repair within 12 months post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Endoleak(s)</measure>
    <time_frame>At 12 months</time_frame>
    <description>Percentage of subjects that experienced endoleak(s) of any type at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Secondary Endovascular Procedures Due to Endoleak</measure>
    <time_frame>Between 30 days and 12 months</time_frame>
    <description>Percentage of subjects that experienced secondary endovascular procedures due to endoleak between 30 days and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Stent Graft Migration</measure>
    <time_frame>Within 12 months post treatment</time_frame>
    <description>Percentage of subjects that experienced stent graft migration within 12 months post treatment, as reported by the CEC. Of note, all migrations resulted from anatomical accommodation of the stent graft. All migrations were at the distal end of the stent graft, moving proximally. No endoleaks were associated to these migrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experience Loss of Stent Graft Patency</measure>
    <time_frame>Within 12 months post treatment</time_frame>
    <description>Percentage of subjects that experience loss of stent graft patency within 12 months post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced One or More Major Adverse Events</measure>
    <time_frame>Within 12 months post treatment</time_frame>
    <description>Percentage of subjects that experienced one or more Major Adverse Events within 12 months post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Died (All-cause Mortality)</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Percentage of subjects that died (all-cause mortality) five years post implant, regardless whether or not the cause of death was related to procedure, device, or condition treated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Aneurysm-related Mortality</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Percentage of subjects that experienced aneurysm-related within five years post implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Aneurysm Ruptures</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Percentage of subjects that experienced aneurysm ruptures within five years post implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Conversions to Open Surgical Repair</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Percentage of subjects that experienced conversions to open surgical repair within five years post implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Type I Endoleaks</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Percentage of subjects that experienced type I endoleaks within five years post implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Type III Endoleaks</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Percentage of subjects that experienced type III endoleaks within five years post implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Type IV Endoleaks</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Percentage of subjects that experienced type IV endoleaks within five years post implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Secondary Endovascular Procedures</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Percentage of subjects that experienced secondary endovascular procedures within five years post implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Stent Graft Migrations (Site Reported)</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Percentage of subjects that experienced stent graft migrations within five years post implant, as reported by the clinical sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Experienced Loss of Stent Graft Patency</measure>
    <time_frame>0 through 1825 days post treatment</time_frame>
    <description>Percentage of subjects that experienced loss of stent graft patency within five years post implant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Thoracic Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Valiant Thoracic Stent Graft System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 subjects were enrolled into the study, including 157 subjects treated with the study device and three subjects classified as intent-to-treat who did not receive the study device.
There were no other arms for this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Valiant Thoracic Stent Graft System</intervention_name>
    <description>Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).</description>
    <arm_group_label>Valiant Thoracic Stent Graft System</arm_group_label>
    <other_name>Valiant device; Valiant stent graft.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The following inclusion/exclusion criteria was obtained from the study protocol.

        INCLUSION CRITERIA

        To be eligible for enrollment, a subject must meet all of the following inclusion criteria:

          1. Subject is between the age of 18 and 85.

          2. Subject must be considered a candidate for elective surgical repair of the TAA (i.e.,
             low-to-moderate risk [categories 0, 1, and 2] per the modified SVS/AAVS scoring system
             at the time of implant). See Appendix B: Modified SVS/AAVS Medical Co-Morbidity
             Grading System

          3. If subject is female of childbearing potential, she must have a negative pregnancy
             test within 7 days before the implant procedure.

          4. Subject has a DTA that is:

               1. A fusiform aneurysm with a maximum diameter of ≥ 5 cm OR is &gt; 2 times the
                  diameter of the non-aneurysmal thoracic aorta;

                  AND/OR

               2. Saccular aneurysm (penetrating atherosclerotic ulcer)

          5. Subject's anatomy must meet all of the following anatomical criteria:

               1. Subject's TAA must be ≥ 20 mm distal to the origin of the left common carotid
                  artery and must be ≥ 20 mm proximal to the celiac artery;

               2. Proximal and distal non-aneurysmal neck diameter measurements must be between 20
                  mm and 42 mm;

               3. Proximal and distal non-aneurysmal neck must be ≥ 20 mm in length.

          6. Thoracic aortic lesion is confirmed, at a minimum, by diagnostic contrast enhanced
             computerized tomography (CT) with optional 3-D reconstruction, and/or contrast
             enhanced Magnetic Resonance Angiogram obtained within four (4) months prior to the
             implant procedure.

          7. Subject is able and willing to comply with the protocol and undergo follow-up
             requirements.

          8. Subject or subject's legal representative understands and has signed an Informed
             Consent approved by the Sponsor and by the IRB for this study.

          9. Subject has patent iliac or femoral arteries or can tolerate a vascular conduit that
             allows endovascular access to the aneurysmal site with the delivery system of the
             appropriate size device chosen for treatment.

        EXCLUSION CRITERIA

        To be eligible for enrollment, a subject cannot meet any of the following exclusion
        criteria:

          1. Planned placement of the COVERED portion of the stent graft requires implant to occur
             in zones 0 or 1.

          2. Subject has a thoracic aneurysm with a contained rupture.

          3. Subject has a connective tissue disease (e.g., Marfan's syndrome, aortic medial
             degeneration).

          4. Subject has a mycotic aneurysm or is suspected of having systemic infection.

          5. Subject has received a previous stent or stent graft or previous surgical repair in
             the DTA.

          6. Subject requires treatment of an infra-renal aneurysm at the time of implant.

          7. Subject has a history of bleeding diathesis, coagulopathy, or refuses blood
             transfusion.

          8. Subject has had or plans to have a major surgical procedure within 30 days before or
             after the Valiant Stent Graft procedure. This does not include planned procedures that
             are needed for the safe and effective placement of the stent graft (i.e.,
             carotid/subclavian transposition, carotid/subclavian bypass procedure).

          9. Subject has had an MI or cerebral vascular accident (CVA) within 3 months.

         10. Subject is currently participating in an investigational drug or device clinical
             trial.

         11. Subject has a known allergy or intolerance to the device components.

         12. Subject has a known hypersensitivity or contraindication to anticoagulants or contrast
             media, which is not amenable to pre-treatment.

         13. Subject has significant and/or circumferential aortic mural thrombus at either the
             proximal or distal attachment sites that would compromise fixation and seal of the
             device.

         14. Subject has other medical, social, or psychological problems that, in the opinion of
             the investigator, preclude him or her from receiving this treatment and the procedures
             and evaluations pre- and post-treatment, or a limited life expectancy of less than 1
             year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Fairman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California - Healthcare Consultation Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute @ Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Altanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Memorial</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Vascular Physicians</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Vascular Associates (Morristown Memorial Hospital)</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shadyside Hospital - University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Episcopal Hospital - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2006</study_first_submitted>
  <study_first_submitted_qc>December 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <results_first_submitted>December 23, 2011</results_first_submitted>
  <results_first_submitted_qc>March 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2012</results_first_posted>
  <last_update_submitted>November 25, 2015</last_update_submitted>
  <last_update_submitted_qc>November 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thoracic Aneurysm</keyword>
  <keyword>Endovascular Aortic Repair (EVAR)</keyword>
  <keyword>Endovascular Stent Graft</keyword>
  <keyword>Endograft</keyword>
  <keyword>Thoracic Aortic Aneurysm</keyword>
  <keyword>Endovascular procedure</keyword>
  <keyword>Descending Thoracic Aneurysm</keyword>
  <keyword>Valiant Stent Graft System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valiant Thoracic Stent Graft System</title>
          <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>0 to 30-day Post Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intend to treat, but not implanted</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>30-day to 365-day Post Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>365-day to 60-month Post Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exited after surgical conversion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valiant Thoracic Stent Graft System</title>
          <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Did NOT Experience Aneurysm-Related Mortality (Post-market Primary Endpoint)</title>
        <description>Evaluation of the ARM-free rate in subjects implanted with the Valiant Thoracic Stent Graft five years post-implantation by comparing it to a pre-defined performance goal (PG) based on an analysis of ARM-free rates from TEVAR data and on results from the VALOR (Talent Thoracic Endoluminal Stent Graft, IDE G980116) clinical study.</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Did NOT Experience Aneurysm-Related Mortality (Post-market Primary Endpoint)</title>
          <description>Evaluation of the ARM-free rate in subjects implanted with the Valiant Thoracic Stent Graft five years post-implantation by comparing it to a pre-defined performance goal (PG) based on an analysis of ARM-free rates from TEVAR data and on results from the VALOR (Talent Thoracic Endoluminal Stent Graft, IDE G980116) clinical study.</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" lower_limit="90.9" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects That Experienced Successful Deployment and Delivery of the Stent Graft at Implant</title>
        <description>Percentage of subjects that experienced successful deployment and delivery of the stent graft at implant. Successful deployment and delivery of the stent graft is used to measure effectiveness.</description>
        <time_frame>At implant</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>160 subjects were enrolled into the study, including 157 subjects treated with the study device and three subjects classified as intent-to-treat who did not receive the study device.
There were no other arms for this study.
Valiant Thoracic Stent Graft System: Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects That Experienced Successful Deployment and Delivery of the Stent Graft at Implant</title>
          <description>Percentage of subjects that experienced successful deployment and delivery of the stent graft at implant. Successful deployment and delivery of the stent graft is used to measure effectiveness.</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="92" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Perioperative Mortality</title>
        <description>Percentage of subjects that experienced perioperative mortality. Perioperative morality is defined as all-cause mortality within 30 days after index procedure.</description>
        <time_frame>Within 30 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Perioperative Mortality</title>
          <description>Percentage of subjects that experienced perioperative mortality. Perioperative morality is defined as all-cause mortality within 30 days after index procedure.</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Paraplegia</title>
        <description>Percentage of subjects that experienced paraplegia within 30 days post treatment</description>
        <time_frame>Within 30 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Paraplegia</title>
          <description>Percentage of subjects that experienced paraplegia within 30 days post treatment</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Successful Aneurysm Treatment (Primary Effectiveness Endpoint)</title>
        <description>Percentage of subjects with absence of both: a) aneurysm growth of more than 5 mm at the 12-month visit relative to the 1-month visit; and b) secondary procedure due to type I or III endoleak performed or recommended at or before the 12-month visit. Success means a subject experienced neither a nor b.
Type I: endoleak in continuity with the proximal anchoring site(proximal endoleak) or the distal anchoring site(distal endoleak)of the device.
Type III: endoleak is present in the mid-graft region due to defect of fabric or between the segments of the modular graft (junctional endoleak).</description>
        <time_frame>At 12-month post procedure</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Successful Aneurysm Treatment (Primary Effectiveness Endpoint)</title>
          <description>Percentage of subjects with absence of both: a) aneurysm growth of more than 5 mm at the 12-month visit relative to the 1-month visit; and b) secondary procedure due to type I or III endoleak performed or recommended at or before the 12-month visit. Success means a subject experienced neither a nor b.
Type I: endoleak in continuity with the proximal anchoring site(proximal endoleak) or the distal anchoring site(distal endoleak)of the device.
Type III: endoleak is present in the mid-graft region due to defect of fabric or between the segments of the modular graft (junctional endoleak).</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="93.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Died (Primary Safety Endpoint: All-Cause Mortality) &gt; &gt;</title>
        <description>The percentage of participants who died within 12-months of the initial procedure, whether or not the cause of death was related to the study device, procedure, or condition treated.
&gt;
&gt; Note: All-cause mortality endpoint is not directly related to successful aneurysm treatment, which pertains to the absence of aneurysm growth and secondary procedure due to Type I and III endoleaks.</description>
        <time_frame>Within 12-months post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Died (Primary Safety Endpoint: All-Cause Mortality) &gt; &gt;</title>
          <description>The percentage of participants who died within 12-months of the initial procedure, whether or not the cause of death was related to the study device, procedure, or condition treated.
&gt;
&gt; Note: All-cause mortality endpoint is not directly related to successful aneurysm treatment, which pertains to the absence of aneurysm growth and secondary procedure due to Type I and III endoleaks.</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="7.3" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Paraparesis</title>
        <description>Percentage of subjects that experienced paraparesis within 30 days post treatment</description>
        <time_frame>Within 30 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Paraparesis</title>
          <description>Percentage of subjects that experienced paraparesis within 30 days post treatment</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.4" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Secondary Procedures Due to Endoleak After Discharge</title>
        <description>Percentage of subjects that experienced secondary procedures due to endoleak after discharge within 30 days post treatment</description>
        <time_frame>Within 30 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Secondary Procedures Due to Endoleak After Discharge</title>
          <description>Percentage of subjects that experienced secondary procedures due to endoleak after discharge within 30 days post treatment</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced One or More Major Adverse Events</title>
        <description>Percentage of subjects that experienced one or more major adverse events within 30 days post treatment, regardless of relatedness to study device</description>
        <time_frame>Within 30 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced One or More Major Adverse Events</title>
          <description>Percentage of subjects that experienced one or more major adverse events within 30 days post treatment, regardless of relatedness to study device</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="30.6" upper_limit="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Aneurysm-related Mortality</title>
        <description>Percentage of subjects that experienced aneurysm-related mortality within 12 months post treatment</description>
        <time_frame>Within 12 months post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device, excluding subjects exited before 12 months and implant failures</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Aneurysm-related Mortality</title>
          <description>Percentage of subjects that experienced aneurysm-related mortality within 12 months post treatment</description>
          <population>Subjects treated or intended to treat with the test device, excluding subjects exited before 12 months and implant failures</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="1.1" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experience Aneurysm Rupture</title>
        <description>Percentage of subjects that experience aneurysm rupture within 12 months post treatment</description>
        <time_frame>Within 12 months post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device excluding subjects that exited before 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experience Aneurysm Rupture</title>
          <description>Percentage of subjects that experience aneurysm rupture within 12 months post treatment</description>
          <population>Subjects treated or intended to treat with the test device excluding subjects that exited before 12 months</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Conversion to Open Surgical Repair</title>
        <description>Percentage of subjects that experienced conversion to open surgical repair within 12 months post treatment</description>
        <time_frame>Within 12 months post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device excluding subjects exited before 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Conversion to Open Surgical Repair</title>
          <description>Percentage of subjects that experienced conversion to open surgical repair within 12 months post treatment</description>
          <population>Subjects treated or intended to treat with the test device excluding subjects exited before 12 months</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Endoleak(s)</title>
        <description>Percentage of subjects that experienced endoleak(s) of any type at 12 months</description>
        <time_frame>At 12 months</time_frame>
        <population>Subjects treated or intended to treat with the test device excluding subjects that did not have proper imaging to identify endoleaks</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Endoleak(s)</title>
          <description>Percentage of subjects that experienced endoleak(s) of any type at 12 months</description>
          <population>Subjects treated or intended to treat with the test device excluding subjects that did not have proper imaging to identify endoleaks</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="7.1" upper_limit="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Secondary Endovascular Procedures Due to Endoleak</title>
        <description>Percentage of subjects that experienced secondary endovascular procedures due to endoleak between 30 days and 12 months</description>
        <time_frame>Between 30 days and 12 months</time_frame>
        <population>Subjects treated or intended to treat with the test device excluding censored subjects (those with no data within the time frame)</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Secondary Endovascular Procedures Due to Endoleak</title>
          <description>Percentage of subjects that experienced secondary endovascular procedures due to endoleak between 30 days and 12 months</description>
          <population>Subjects treated or intended to treat with the test device excluding censored subjects (those with no data within the time frame)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Stent Graft Migration</title>
        <description>Percentage of subjects that experienced stent graft migration within 12 months post treatment, as reported by the CEC. Of note, all migrations resulted from anatomical accommodation of the stent graft. All migrations were at the distal end of the stent graft, moving proximally. No endoleaks were associated to these migrations.</description>
        <time_frame>Within 12 months post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device, excluding subjects that did not have proper imaging</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Stent Graft Migration</title>
          <description>Percentage of subjects that experienced stent graft migration within 12 months post treatment, as reported by the CEC. Of note, all migrations resulted from anatomical accommodation of the stent graft. All migrations were at the distal end of the stent graft, moving proximally. No endoleaks were associated to these migrations.</description>
          <population>Subjects treated or intended to treat with the test device, excluding subjects that did not have proper imaging</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0.6" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experience Loss of Stent Graft Patency</title>
        <description>Percentage of subjects that experience loss of stent graft patency within 12 months post treatment</description>
        <time_frame>Within 12 months post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device, excluding subjects that did not have proper imaging</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experience Loss of Stent Graft Patency</title>
          <description>Percentage of subjects that experience loss of stent graft patency within 12 months post treatment</description>
          <population>Subjects treated or intended to treat with the test device, excluding subjects that did not have proper imaging</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced One or More Major Adverse Events</title>
        <description>Percentage of subjects that experienced one or more Major Adverse Events within 12 months post treatment</description>
        <time_frame>Within 12 months post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device, excluded subjects that exited before 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced One or More Major Adverse Events</title>
          <description>Percentage of subjects that experienced one or more Major Adverse Events within 12 months post treatment</description>
          <population>Subjects treated or intended to treat with the test device, excluded subjects that exited before 12 months</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" lower_limit="40.6" upper_limit="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Died (All-cause Mortality)</title>
        <description>Percentage of subjects that died (all-cause mortality) five years post implant, regardless whether or not the cause of death was related to procedure, device, or condition treated</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Died (All-cause Mortality)</title>
          <description>Percentage of subjects that died (all-cause mortality) five years post implant, regardless whether or not the cause of death was related to procedure, device, or condition treated</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Aneurysm-related Mortality</title>
        <description>Percentage of subjects that experienced aneurysm-related within five years post implant</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Aneurysm-related Mortality</title>
          <description>Percentage of subjects that experienced aneurysm-related within five years post implant</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Aneurysm Ruptures</title>
        <description>Percentage of subjects that experienced aneurysm ruptures within five years post implant</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Aneurysm Ruptures</title>
          <description>Percentage of subjects that experienced aneurysm ruptures within five years post implant</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Conversions to Open Surgical Repair</title>
        <description>Percentage of subjects that experienced conversions to open surgical repair within five years post implant</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Conversions to Open Surgical Repair</title>
          <description>Percentage of subjects that experienced conversions to open surgical repair within five years post implant</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Type I Endoleaks</title>
        <description>Percentage of subjects that experienced type I endoleaks within five years post implant</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Type I Endoleaks</title>
          <description>Percentage of subjects that experienced type I endoleaks within five years post implant</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Type III Endoleaks</title>
        <description>Percentage of subjects that experienced type III endoleaks within five years post implant</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Type III Endoleaks</title>
          <description>Percentage of subjects that experienced type III endoleaks within five years post implant</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Type IV Endoleaks</title>
        <description>Percentage of subjects that experienced type IV endoleaks within five years post implant</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Type IV Endoleaks</title>
          <description>Percentage of subjects that experienced type IV endoleaks within five years post implant</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Secondary Endovascular Procedures</title>
        <description>Percentage of subjects that experienced secondary endovascular procedures within five years post implant</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Secondary Endovascular Procedures</title>
          <description>Percentage of subjects that experienced secondary endovascular procedures within five years post implant</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Stent Graft Migrations (Site Reported)</title>
        <description>Percentage of subjects that experienced stent graft migrations within five years post implant, as reported by the clinical sites</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Stent Graft Migrations (Site Reported)</title>
          <description>Percentage of subjects that experienced stent graft migrations within five years post implant, as reported by the clinical sites</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Experienced Loss of Stent Graft Patency</title>
        <description>Percentage of subjects that experienced loss of stent graft patency within five years post implant</description>
        <time_frame>0 through 1825 days post treatment</time_frame>
        <population>Subjects treated or intended to treat with the test device</population>
        <group_list>
          <group group_id="O1">
            <title>Valiant Thoracic Stent Graft System</title>
            <description>Subjects treated or intended to treat with the test device (Valiant Thoracic Stent Graft System).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Experienced Loss of Stent Graft Patency</title>
          <description>Percentage of subjects that experienced loss of stent graft patency within five years post implant</description>
          <population>Subjects treated or intended to treat with the test device</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Valiant Thoracic Stent Graft System</title>
          <description>160 subjects were enrolled into the study, including 157 subjects treated with the study device and three subjects classified as intent-to-treat who did not receive the study device.
There were no other arms for this study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Endocardial fibroelastosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Complication of device insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Unknown cause of death. Overall in the study, there were 54 deaths (46 not related to the TAA; 8 related to the TAA). However, this death could not be classified any further, as site was unable to obtain any information associated to it.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Device deployment issue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <description>Right prosthetic knee infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <description>TAA endoleaks: Type I, 9 events; Type II, 3; Type V/Unknown, 3. AAA endoleaks: 2 events</description>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonia herpes viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Asbestosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Eyeball rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IIIB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Spinal cord ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <description>E.g., Confusion, aphasia, and disorientation</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bladder catheter replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <description>Includes non-treated aneurysm, such as abdominal aneurysms, and aneurysm expansion of treated aneurysms</description>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Peripheral artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Splenic embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="21" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <description>TAA endoleaks: Type I, 6 events; Type II, 20; Type III, 1; Type IV, 2; Type V/Unknown, 5. AAA endoleaks: 3 events.</description>
                <counts group_id="E1" events="37" subjects_affected="32" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="35" subjects_affected="32" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <description>E.g. Confusion, worsening memory, and anxiety</description>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <description>Includes non-treated aneurysm, such as abdominal aneurysms, and aneurysm expansion of treated aneurysms</description>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator (PI) and institution agree not to publish the results of the study until after the earliest of the following: a)conclusion of the study, b)the early termination of the study, c)at discretion and approval of the sponsor, or d)after sponsor confirms there will be no multicenter study publication, whichever occurs first. PI and institution further agree to submit to sponsor copies of any proposed publication or public presentation at least sixty days before dissemination.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Adverse Events and Serious Adverse Events listed in ClinicalTrials.gov were re-coded, using MedDRA 13.1. To do so, events were reclassified. As a result, data in listings may not match those in Clinical Update reports, SSEDs, or Instructions for Use.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>PJ Belmont, Clinical Research Specialist</name_or_title>
      <organization>Medtronic Vascular, Inc.</organization>
      <phone>707-480-3025</phone>
      <email>PJ.Belmont@Medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

